Home > News > Altair Nanotechnologies Announces New Preclinical Testing
February 5th, 2004
Altair Nanotechnologies Announces New Preclinical Testing
Altair Nanotechnologies, Inc., a developer and manufacturer of innovative nanomaterial products, announced that it is planning to conduct new preclinical testing of its drug candidate, RenaZorb. The test will use an animal model directly comparing RenaZorb with existing and proposed drugs for phosphate control in patients with End Stage Renal Disease undergoing dialysis. The testing is expected to be initiated within 30 to 45 days. The company also announced that it plans to file an IND application with the U.S. Food and Drug Administration.
Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes March 4th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015
Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015